After relapse , residual disability of 0.5 EDSS points remained in 31 % of natalizumab and 45 % of placebo patients ( P = 0.0136 ) ( mean post-relapse residual EDSS increase : natalizumab = 0.06 ; placebo = 0.28 ; P = 0.0170 ) .